Kisqali (Ribociclib Tablet) 200mg

Ribociclib works by selectively inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in the regulation of the cell cycle. This inhibition leads to cell-cycle arrest in the G1 phase and prevents the proliferation of tumor cells, thereby slowing the progression of cancer.

The usual dose of Kisqali is determined by a healthcare provider based on the patient's condition and response to treatment. It is typically taken as 600 mg (three 200 mg tablets) once daily for 21 days, followed by 7 days off, forming a 28-day treatment cycle.

Kisqali should be avoided during pregnancy due to potential risks to the fetus. It is also not recommended to breastfeed while taking Kisqali. Always consult with a healthcare provider for personalized advice.

To order Kisqali from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping, and the import paperwork.

Kisqali is a CDK4/6 inhibitor, which is a relatively newer class of drugs compared to traditional chemotherapy or hormone therapy. It is specifically indicated for HR+, HER2-negative breast cancer and is used in combination with other therapies. The choice of treatment depends on the specific characteristics of the cancer and the patient's overall health.

Kisqali should be stored at room temperature in its original package, protected from light and moisture. It should be kept out of the reach of children. Always follow the storage instructions provided by the manufacturer.

Kisqali is taken orally as a tablet. The tablets should be swallowed whole with a glass of water and should not be crushed or broken. It is important to take the medication at approximately the same time each day, whether with food or on an empty stomach.

The most serious risks associated with Kisqali include neutropenia (low white blood cell count), liver toxicity, QTc prolongation (heart rhythm abnormality), and interstitial lung disease. Regular monitoring and prompt reporting of any unusual symptoms to a healthcare provider are essential.

Kisqali should not be used by individuals who are allergic to ribociclib or any of its ingredients. It should also be avoided during pregnancy and breastfeeding. Patients with certain medical conditions or those taking specific medications that interact with Kisqali should consult their healthcare provider before starting treatment.